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the assessment of new diagnostic tests. Invest Radiol 1995;30: 
334-340.
r a t i o n a l e  a n d  o b j e c t i v e s .  Because new diagnostic 
tests become available rapidly, the authors determined a need 
for proper assessment of tests before their implementation in 
clinical practice. Three factors are of pivotal importance: the 
selection of the proper study population, the determination of 
the diagnostic power including its related statistical analysts, 
and the relation of the new test to current diagnostic tools. Pa­
tients suspected of having a disease are those who would benefit 
from the application of a new test. Therefore, only those pa­
tients need be involved in the assessment study.
METHODS. Summary measures of diagnostic power other 
than sensitivity and specificity are advocated because these con­
ventional measures depend on cutoff points and are susceptible 
to selection bias. The relation between the new test and existing 
diagnostic tools must be established to determine if the new test 
contributes to the diagnostic process.
r e s u l t s  a n d  c o n c l u s i o n .  To avoid waste of effort and
money, the authors suggest a prudent assessment approach in 
phases. Whereas the initial challenge consists of selection of an 
adequate patient population, subsequently all determinants of 
disease (signs, symptoms, comorbidity, and other diagnostic 
factors) and factors influencing the decision to use a test (pa­
tient burden and cost) are considered.
Ma n y  n e w  d i a g n o s t i c  tests have been developed and introduced into clinical practice in recent 
years. Consequently, a need has developed for proper as­
sessment o f tests before im plem entation . While consen­
sus exists as to necessity o f a phased assessment of a new 
drug, this is not the case for diagnostic tests. Three factors 
are of central im portance in diagnostic test assessment:
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(1) the selection of the proper study population, (2) the 
determ ination of diagnostic power with its related statis­
tical analysis, and (3) the comparison of the new test with 
current diagnostic tools.
For assessment of a test, usually the test results of 
healthy people are compared with those of patients al­
ready known to have a given disease: the easily accessible 
population. In clinical practice, however, the test is used 
to  distinguish between the presence and absence of dis­
ease am ong patients having certain symptoms and m an­
ifesting particular signs. In this so-called “ indicated” 
population, it is more difficult to discriminate between 
suspected patients with the illness and those without, be­
cause it is highly probable that the test outcome is asso­
ciated with complaints, signs, or symptoms of the study 
patients. It is the assessment in an indicated population 
in  which we are ultimately interested.1
T he second point to be stressed in assessment studies 
is the definition of diagnostic power and the associated 
statistical and analytical methods. Commonly, diagnos­
tic power is ascribed to  a qualitative diagnostic test if it 
yields a higher test result more frequently in the diseased 
group than  in the nondiseased group. The results of 
quantitative tests often are dichotomized, usually at the 
95th percentile of the test result distribution in healthy 
persons,2 so as to make the test a qualitative one. Dichot- 
om ization deprives a test of its full informative content, 
and thus may lead to substantial loss of information. 
Furtherm ore, it makes assessment of results dependent 
on the cutoff point and susceptible to selection bias.3 Se­
lection bias can occur as a result of differential verifica­
tion for patients with positive and negative test results,4 
or as a result o f  studying only a part o f the entire disease 
spectrum ,5 as is done in an easily accessible population.
Finally, it also is im portant to determine the relative 
value o f  the new test and existing diagnostic tools to de­
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termine if the new test has diagnostic valve. It m ight be 
possible to eliminate one or more of the older tests or, 
indeed, the new test. In this article, we elaborate on these 
factors and incorporate them into guidelines for a phased 
assessment of new diagnostic tests.
Diagnostic Process
Generally, patients visit a doctor because they are ex­
periencing certain symptoms. The doctor will, implic­
itly, list diseases that are typically attended by the com ­
plaints, signs, and symptoms that the patient is encoun­
tering,6 A probability of disease presence, depending on 
the frequency with which the doctor sees these diseases, 
is assigned to each disease on the list. If one probability 
is high enough, treatm ent will be initiated. I f  no proba­
bility is high enough, a diagnostic test will be performed. 
Whether a probability is sufficiently high to warrant 
treatment or the use of a diagnostic test cann ot be deter­
mined in general terms. It highly depends on the benefit 
o f the treatment, the risk or cost of the diagnostic test, 
and the cost of treatm ent for patients who do no t actually 
have the disease, but may be treated because of a false- 
positive test result.5,7 The assigned probabilities of dis­
ease presence are adjusted for each disease on the basis 
of a test result.
Current Assessment Practice
For assessment of a test, the test results of healthy peo­
ple are compared with those of patients already known 
to have the disease. Diagnostic power is ascribed to a 
qualitative diagnostic test if it yields a higher test result 
more frequently in the diseased group than in the non­
diseased group. For example, mean serum concentra­
tions of carcinoembryonic antigen were higher in pa­
tients with colorectal carcinoma than in healthy individ­
uals, therefore it was long believed that carcino­
embryonic antigen might be a suitable diagnostic test for 
colorectal carcinoma. The results of quantitative tests of­
ten are dichotomized, usually at the 95th percentile of 
the test result distribution in healthy persons,2 so as to 
make the test qualitative. Frequently, assessment is con­
sidered appropriate when the sensitivity and specificity 
of a new test are determined.
Problems W ith Current Assessment Practice
The well-known parameters, sensitivity and  specific­
ity, o f  the applied test, to be calculated from a basic table 
such as Table 1, are useful for updating the probability 
o f disease presence according to Bayes’ theorem.5,8 Table 
2 shows how the probability of disease in the presence of 
a positive test result is calculated with Bayes’ theorem in 
the notation of conditional probabilities. Thus, in diag­
nosis, a strong need exists to know the information a test 
result yields (eg, by giving the sensitivity and specificity).
TABLE 1. Information of a Dichotomous Diagnostic Test as
Presented in a Fourfold Table
Disease
Present Absent
Test result Positive 320 60 380
Negative 80 540 620
Total 400 600 1000
Sensitivity: proportion of diseased with positive test result = 320/ 
400 = 80%.
Specificity: proportion of non-dlseased with negative test result = 
540/600 = 90%.
Prevalence of disease in test-positive group = 320/380 = 84%; of­
ten referred to as positive predicted value.
Prevalence of disease in test-negative group = 80/620 = 13%; also 
known as 1 minus negative predictive value.
In assessment studies of new tests, estimates of these test 
“ characteristics” predom inantly are presented as assess­
m ent results. Unfortunately, sensitivity and specificity 
do not always provide the relevant inform ation for this 
purpose, mainly because of their dependency on cutoff 
points and their susceptibility to selection bias.
M any diagnostic tests yield results that are not just 
positive or negative, but have a wider range, such as the 
percentage occlusion of an artery as judged from angiog­
raphy. To calculate sensitivity and specificity, the possi­
ble test results m ust be dichotomized. A cutoff point for 
test positivity m ust be chosen; for example, a result 
higher than 70% is positive and should result in patient 
referral for surgery. By doing so, the different diagnostic 
information of 50% stenosis or 90% stenosis is not taken 
into account. Thus, dichotom ization deprives a test o f its 
full informative content and m ay lead to substantial loss 
of information. Furtherm ore, it makes assessment re­
sults dependent on the cutoff point and susceptible to 
selection bias.4
Selection bias can occur as a result o f  differenti al veri­
fication for patients with positive and negative test re­
sults,4 or as a result o f studying only a part o f  the entire 
disease spectrum .5 Results o f a new test usually are com ­
pared with results from patients already diagnosed with 
the disease: the easily accessible population. In clinical 
practice, however, the test is used to distinguish between 
the presence and absence of disease am ong patients hav­
ing certain sym ptom s and manifesting particular signs. 
In this indicated population, it is m ore difficult to dis­
crim inate between suspected patients with the illness and 
those without because test results often are associated 
with the complaints, symptoms, or signs of study pa­
tients, Consequently, sensitivity and specificity results of 
tests that are applied to  a population that was selected 
differently than  the population in which the test was as­
sessed cannot be extrapolated to the new population.9 It
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TABLE 2. Bayes’ Theorem
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Bayes’ theorem in terms of conditional probabilities Bayes’ theorem in a more practical notation
P(D+)X P (T+|D+)
P(D+| H P(D+1T+) =
P(D+) X P(T+1D+) + P(D~) X P(T+|D_)
P(D+) X Sensitivity
P(D+) X Sensitivity + 1 — P(D+) X Specificity
D; disease outcome (present/absent); T: test result (positive/negative).
is the assessment result from an indicated population in 
which we are ultimately interested.10,11
Consider, for example, a population in which 60% has 
complaints. The results o f  the diagnostic test used corre­
late perfectly with the presence or absence of complaints. 
Two thirds of patients with com plaints have the disease, 
and three quarters of patients w ithout complaints do not 
have the disease. The prevalence of disease is 50% (Table 
3). In this population, the sensitivity rate of the test is 
80%, and the specificity rate is 60%. In a second popula­
tion, only 40% has complaints, therefore, the distribu­
tion of disease presence and absence in patients with and 
without complaints is the same as in the first population. 
Thus, two thirds of the patients with complaints have the 
disease and three quarters of the patients without com ­
plaints do not have the disease (Table 4). In this popula­
tion, the sensitivity rate o f  the same test is 64%, and the 
specificity rate is 78%. Thus, the composition o f the pa­
tient population is one of the determ inants of sensitivity 
and specificity. These param eters are not constant char­
acteristics of a test, but vary with the distribution o f com ­
plaints, symptoms, and signs.
In our opinion, it also is im portant to establish the rel­
ative value of the new test and existing diagnostic tools 
to  determine whether the new test contributes as a diag­
nostic tool. It might be possible to  eliminate one or more 
older diagnostic tests or, indeed, the new test.
When assessing the diagnostic value o f a new test, it 
m ust be compared with a generally accepted reference 
method, or a gold standard. In m any instances, gold 
standards do not exist or are not ethically justifiable to 
carry out on all patients (eg, surgery or autopsy). In such 
instances, appropriate fallible reference methods may be 
used, such as the generally accepted diagnostic reference 
test, clinical follow-up for a fixed tim e period, or re­
sponse to  therapy.
TABLE 3. Hypothetical Distribution of Test Results and Disease
Presence-1
Disease Disease
present absent Total
Test result Positive 40 20 60
Negative 10 30 40
Total 50 50 100
Assessment in Phases
The m ain challenge in diagnostic test assessment is se­
lection of an adequate study population. Ultimately, this 
population consists of indicated patients. To avoid waste 
o f  effort and money, it must be established as soon as 
possible whether a diagnostic test is potentially worth­
while. This can be achieved by a prudent assessment in 
several phases.12' 17 It is not necessary that all new tests 
undergo the entire assessment procedure. In some in­
stances, it is established quickly that test outcomes 
am ong diseased and nondiseased patients are virtually 
identical. In th a t case, the test is not yet adequate.
Test D evelopm ent
Strictly speaking, the development of a diagnostic test 
does not fall within the scope of test evaluation and will 
no t be elaborated further. Nevertheless, it is important 
tha t some facts o f  the new test are known before actual 
assessment starts. Among these are the following.
1. M inim um  detection level and cross-reactivity in 
the case of a biochemical test: for a useful diagnos­
tic test, all individuals undergoing the test, regard­
less o f whether they have the disease, should have 
test results that are higher than the minimum de­
tection level of the test. Furthermore, the biochem­
ical test should only react with the substance of in­
terest (eg, a specific serum tum or marker) and not 
with other substances.
2. M easurem ent errors: large random  measurement 
errors m ake potential diagnostic tests useless be­
forehand.
3. Repeatability, which must be high, otherwise the 
test will never meet diagnostic assessment stan­
dards.
TABLE 4. Hypothetical Distribution of Test Results and Disease
Presence-2
Disease
Present Absent Total
Test result Positive 27 13 40
Negative 15 45 60
Total 42 58 100
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4. Required personnel and equipment.
5. Acceptability of the test for patients. A test can 
have very good discriminative power; however, if 
it poses risk of morbidity or even mortality to  the 
patients, such as coronary angiography, applica­
tion of the test will be limited only to patients with 
a very strong suggestion of disease presence.
6. Dose and pharmacokinetics in the case of a phar­
maceutical test, etc.
Test Application in an Easily Accessible Population
To carry out an assessment in an easily accessible pop­
ulation can only be useful from a pragmatic and logistic 
point of view. If the test performs badly here, which is 
not uncom m on, it will certainly perform worse in the 
indicated population. This phase can be regarded as a 
“quick and  dirty '’ assessment method. An easily accessi­
ble population could be, for instance, a population of d i­
agnosed patients and healthy individuals. We are no t 
concerned with the occurrence of selection bias or other 
problems at this point. If a test does not have sufficient 
discriminative power in this phase of diagnostic test as­
sessment, the assessment procedure can be stopped. The 
test needs further development.
Test Application in the Indicated Population
This essential assessment phase of the “ indicated11 
population should take place in a population of patients 
who are judged eligible for the new test in a real clinical 
situation because of the suspicion that they have the ill­
ness at issue. In this phase, therefore, we are concerned 
with the selection of the relevant patient population. A d­
equate selection of patients is achieved by gathering a 
consecutive series of all as yet undiagnosed patients sus­
pected of having the disease at issue on the ground o f 
their complaints, signs, and symptoms.18
Diagnostic Profile
At this stage of the assessment process, it is im portant 
to establish the contribution of the new test to the exist­
ing diagnostic arsenal, including other diagnostic tests, 
the nonclinical profile (eg, age, gender), the clinical p ro ­
file (complaints, symptoms, and signs) and comorbidity. 
If the new test cannot add diagnostic power to the exist­
ing arsenal, it should be questioned seriously whether in ­
troduction of the test into clinical practice is desirable. 
Only if the test has other relevant characteristics, such as 
cheapness or safeness, introduction can be considered. 
In this phase, it also is necessary to study only patients o f 
the proper indicated population. To obtain the diagnos­
tic information of the new test alone, the outcomes of all 
other diagnostic tests in use must be known as well, 
which necessitates the concurrent measurement o f those 
tests.
M edica l Technology A ssessm ent
The last challenge for the new test is a medical tech­
nology assessment, including selection and  order o f di­
agnostic tests, cost-effectiveness, patien t’s utilities or 
preference measurements, etc. The new test can be used 
as the first test after the history has been taken and phys­
ical examination has been carried out. However, it is also 
possible that the new test is so expensive that to apply it 
to all patients is not justified, such as in cases where the 
natural course of the disease is not life-threatening. In 
this phase, questions of therapeutic efficacy (did treat­
m ent or patient m anagem ent change?), patient outcom e 
efficacy (did life expectancy improve?) and, if possible, 
societal efficacy (are costs acceptable for society?) should 
be answered.19
Because there are so m any questions involved in the 
final phase of test assessment, the best way to deal with 
them  probably is to carry out a clinical trial in the  indi­
cated population, with random  allocation of the new 
test. Test results will have therapeutic consequences and 
the only proper way to study such an intended effect is a  
random ized controlled trial.
Necessary Knowledge
Before test assessment can be carried out in any study 
population, certain inform ation has to be made explicit. 
First, the population in which the test is assessed should 
be defined carefully. Also, the ultim ate realization of the 
study population has to be described, while indicating 
whether the investigators succeeded in gathering all con­
secutive patients or not. This gives an indication of the 
potential selection bias contracted by the actual study 
population. Even an indicated population will yield bi­
ased assessment results when selective uptake or loss o f  
participants has taken place*
Secondly, the diagnostic test m ust be described clearly 
and test results presented accordingly. This includes 
specifying the type of results it yields. Test results may be 
m easured qualitatively or quantitatively. M any tests are 
quantitative but have been converted to qualitative tests. 
An example of such a test is the hemoglucotest, which 
measures glucose concentration in blood. The test is de­
signed so that at a certain blood glucose concentration 
the color o f the test strip changes to blue.
If  tests are inherently qualitative, it is possible to assign 
a judgm ent probability of the presence of disease to the 
test result to  create a quantitative test result. In the  D utch 
screening program for breast cancer with m am m ography 
it is com m on practice to judge the presence of m alignant 
lesions on m am m ogram s in term s o f “ not present, not 
probable, indecisive, probable, certain.1’
If judgm ent o f the test result is done by different ob­
servers, they should be standardized to diminish interob­
server variation as m uch as possible. New observers
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should be trained by experienced observers and every 
once in a while consensus meetings might be arranged. 
However, interobserver variation will never be elimi­
nated entirely. If an apparatus is simple to read, in terob­
server variation may not be a problem, but systematic 
measurement errors of the apparatus should be known 
for the machine to be calibrated as often as necessary. 
Standardization is im portant to eliminate systematic 
differences, but for tests involving a reader’s subjective 
interpretation, interobserver variation cannot be elimi­
nated. Here, consensus and dual reading are tools for 
standardization.
Finally, the m anner o f verification of disease status 
should be stated for all patients in the investigation. 
Sometimes all patients can be subjected to  the gold stan­
dard, but often, for ethical reasons, clinical follow-up for 
a restricted period of tim e must be used as the criterion, 
at least for part o f the study population, and in particular 
for patients with negative test results. Occasionally, veri­
fication relies on the prescription of and subsequent re­
action to a medication, for instance a certain pharm a­
ceutical Calculation of test param eters such as sensitiv- 
ity and specificity should not be restricted to those 
patients who were subjected to the real gold standard. In 
that case, the param eter estimates will be biased; this 
type of bias is called verification bias.20
All relevant patient characteristics, test results, and the 
ultimate diagnosis should be registered individually for 
every patient, including missing data. W ith all this infor­
mation available, insight is gained into the potential bias 
of assessment measures, and the extent and direction o f 
possible bias.
Statistical Analyses
For qualitative tests— measuring the test result on a 
presence/absence scale— com m only used measures o f 
test performance are sensitivity and specificity, calcu­
lated from a fourfold table, or likelihood ratios, to be cal­
culated from a fourfold table or a  2 X k table— in case 
the test results are measured in k categories (Table l).21 
For quantitative tests, with test results in more than  two
TABLE 5. Distribution of Duplex and Angiography Results of
Carotid Arteries in a 2*k Table
Angiography % 
stenosis
71-99 <70 Total
Duplex % stenosis 71-99 7 22 29
51-70 10 1 11
31-50 0 15 15
^30 0 22 22
Total 17 60 77
TABLE 6. Distribution of Duplex and Angiography Results of
Carotid Arteries in a 2*2 Table
Angiography % 
stenosis
71-99 <70 Total
Duplex % stenosis >30 17 38 55
¿30 0 22 22
Total 17 60 77
ordinal categories or on a continuous scale, it is recom­
m ended to  present all the information they provide. This 
can be achieved by presenting receiver operating charac­
teristic (ROC) curves22 and cumulative probability dis­
tributions.23
An RO C curve displays sensitivity versus 1 minus 
specificity at as m any cutoff points as possible.22,24 Re­
ceiver operating characteristic curves are thus indepen­
dent of cutoff points and yield the area under the curve as 
a sum m ary m easure of diagnostic performance.25,26 The 
construction of R O C  curves is as follows. Consider the 
Duplex test for assessment of carotid stenosis. This test 
was assessed in 77 carotid arteries end carotid angiogra­
phy was perform ed in all of them  as the gold standard. 
The new test m ust be able to determine whether a patient 
should have a carotid endarterectomy (stenosis 71 to 
99%) or not (Table 5). At each possible cutoff point the 
table is condensed to  a 2 X 2 table and sensitivity and 
specificity are calculated. For example, when the Duplex 
criterion o f >30%  stenosis is used as cutoff point for test 
positivity, the  table simplifies to Table 6. The sensitivity 
then is 100% and the specificity is 37%. Next, sensitivity 
and 100% m inus specificity are plotted against each 
other in an RO C curve (Figure 1).
Furtherm ore, different tests assessed in one popula­
tion can be com pared easily, and the ROC curve is rela­
tively stable to  verification bias.3'4 Cumulative frequency 
distributions provide clinicians with the sensitivity and 
specificity of a test a t any cutoff point requested.
There is a tendency to present the prevalence of illness 
by groups of test results,1 because this is the proportion 
we are naturally interested in: given a certain test result, 
what is the probability that disease is present? This 
makes sense only when the actual study population has 
been gathered in ignorance, and therefore indepen­
dently, o f the true disease status.
Prevalence of disease can be calculated for patients 
with a positive test result and for patients with a negative 
test result, as well as for the various categories of test re­
sults for a quantitative test. In the case of a perfectly dis­
crim inating test, prevalence in the lower categories of the 
test result would be 0, whereas the prevalence of disease
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S ensitiv ity  (% )
100%  m inus S pecific ity
Fig. 1. Receiver operating characteristic curve for Duplex measure­
ments of carotid artery stenosis.
in the higher would be L If the prevalence of disease con­
ditional on clinical and nonclinical profile, comorbidity, 
and other diagnostic test results is required, logistic re­
gression analysis is an attractive way of estimating this 
so-called prevalence function.10 According to the pres­
ence or absence of a feature or the result of a diagnostic 
test for an individual patient, data is substituted in the 
prevalence function, and the probability of having the 
disease can be calculated.27
As in all analyses, missing values on test outcome or 
disease status have to be dealt with properly, for instance 
as separate categories, rather than removed from the 
analyses and wholly disregarded.28
Conclusion
Guidelines have been presented with recommenda­
tions for the design and statistical analysis of assessment 
studies. With respect to the patient population, it was ex­
plained that patients with a clinical indication for the test 
form the only adequate population. Patients have an in ­
dication for a test because they are suspected of having 
the disease that the test is supposed to diagnose. W ith 
respect to the statistical analysis, a plea for the use o f 
ROC curves and logistic regression analysis was made. 
Receiver operating characteristic curves use the full in ­
formation content of a diagnostic test, in case the test is 
measured on an ordinal or continuous scale. With logis­
tic regression analysis, the contribution of the new test to 
the existing diagnostic arsenal can be estimated.
Good guidelines for diagnostic test assessment could 
prevent the introduction o f disappointing diagnostic 
tests before they are fully im plem ented in clinical prac­
tice.29 Although a phased assessment is no t foolproof, it 
is highly likely that the chances of detecting a useless test 
are increased by introducing such an assessment proce­
dure. This is illustrated aptly by the example o f phased 
medical drug evaluation.
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